Team
health

DAPT Calculator

The DAPT score quantifies the trade-off between stent thrombosis prevention and bleeding complications in patients completing one year of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention. Cardiologists use this tool to decide whether extending treatment beyond 12 months reduces recurrent events more than it increases major bleeding risk. The scoring system weighs clinical risk factors including age, diabetes, prior cardiac events, and heart function to stratify patients into high-risk (continue DAPT) or low-risk (switch to aspirin monotherapy) groups.

Last updated:

Creators Adena Benn, BSc
2,116 people find this calculator helpful

What is DAPT and when is it prescribed?

Dual antiplatelet therapy combines two drugs—typically aspirin and a thienopyridine (clopidogrel, prasugrel, or ticagrelor)—to prevent platelets from aggregating around coronary stents. This combination therapy is standard for the first 12 months after percutaneous coronary intervention (PCI), when the risk of stent thrombosis is highest.

The challenge arises after this initial year. Continuing DAPT reduces stent thrombosis and recurrent myocardial infarction but increases major bleeding events. Conversely, stopping one agent and reverting to aspirin alone minimises bleeding risk but allows modest elevation in ischaemic complications. Individual patient characteristics—age, renal function, prior bleeds, diabetes severity, and comorbidities—determine which strategy offers greater net benefit.

The DAPT score was developed to move beyond one-size-fits-all recommendations and provide a personalised risk assessment.

DAPT Score Calculation

The DAPT score sums points from nine clinical variables and applies an age-based adjustment. Most risk factors contribute one point if present; congestive heart failure or ejection fraction below 30% and venous graft stents are weighted at two points each.

DAPT Score = Σ (age points + diabetes + prior MI + acute MI + stent type + venous graft + CHF/LVEF<30% + smoking + PE stent)

Age adjustment:

Age ≥75 years: −2 points

Age 65–74 years: −1 point

Age ≤64 years: 0 points

  • Age — Patient age in years; older patients receive point deductions
  • Diabetes — Presence of diabetes mellitus requiring medication
  • Prior MI — History of myocardial infarction before the current intervention
  • Acute MI — Presentation with acute ST-elevation or non-ST-elevation MI
  • Stent type — Complex stent anatomy or bifurcation requiring multiple stents
  • Venous graft — Intervention on a saphenous vein graft (saphenous vein graft stent scores 2 points)
  • CHF/LVEF — Congestive heart failure or left ventricular ejection fraction below 30% (scores 2 points)
  • Smoking — Current or recent smoking history
  • Ejection fraction stent — Stent placement in patient with reduced ejection fraction

Interpreting your DAPT score

The final DAPT score ranges from −2 to +10. Scores fall into two broad categories:

  • Score ≥2 (high ischaemic risk): Prolonged DAPT beyond 12 months offers net clinical benefit. These patients experience more benefit from stent thrombosis prevention than harm from extended bleeding risk. Continuing dual therapy for 24 to 30 months is typically recommended.
  • Score ≤1 (low ischaemic risk): Switching to aspirin monotherapy after 12 months is preferred. Bleeding risk outweighs ischaemic benefit, making single-agent therapy safer and equally effective.

The boundary between these groups is deliberate: patients with a score of exactly 1 sit at the clinical equipoise and warrant shared decision-making with their cardiologist. Individual bleeding history, renal function, compliance, and procedural success all influence the final treatment decision alongside the DAPT score.

Clinical Considerations When Using DAPT Score

Several factors and pitfalls deserve attention when interpreting the score and guiding treatment duration.

  1. Age paradox and frailty — Although older patients receive point deductions and often score lower, they may actually tolerate bleeding worse due to comorbidities and polypharmacy. A score of −1 or 0 in an octogenarian with anaemia or renal impairment may still warrant careful assessment of absolute versus relative benefits.
  2. Bleeding history trumps score — Patients with prior major bleeding, intracranial haemorrhage, or gastrointestinal ulceration should strongly consider early cessation despite a high DAPT score. The calculator estimates group-level risk; individual contraindications and prior adverse events override the numerical result.
  3. Dynamic risk recalibration — The DAPT score predicts risk for years 1–2 after PCI. New clinical events (recurrent MI, stent thrombosis, major bleeding) during or after the first 12 months change the risk-benefit calculus. Reassess with your cardiologist if complications occur.
  4. Medication adherence and access — Dual antiplatelet therapy requires strict adherence and continuous supply. Poor compliance or cost barriers may argue for simplification to monotherapy earlier, even with a higher DAPT score. Discuss practical feasibility openly with your healthcare team.

Limitations and when to seek expert counsel

The DAPT calculator provides evidence-based numerical guidance but cannot account for every clinical nuance. Variables such as lesion complexity, number of stents, prior bleeds, liver disease, thrombophilia, and concurrent anticoagulation (for atrial fibrillation or mechanical valves) are not captured in the score but profoundly influence the decision.

Patients on triple therapy (dual antiplatelet agents plus warfarin or novel oral anticoagulant) face compounded bleeding risk and require cardiology and anticoagulation specialist input. Similarly, planned surgery, dental procedures, or endoscopy within the treatment window necessitates temporary interruption of antiplatelet therapy, introducing procedural and bridging considerations outside the scope of the calculator.

Always discuss your DAPT score result with your interventional cardiologist or heart specialist. This tool informs rather than replaces clinical judgment and shared decision-making.

Frequently Asked Questions

Can I stop one antiplatelet drug before 12 months if my bleeding risk is high?

Early cessation of DAPT (before 12 months) substantially increases stent thrombosis risk and should only be considered in life-threatening bleeding scenarios. Even then, temporary interruption is preferred over permanent discontinuation. If you have a high bleeding score or baseline risk factors, discuss alternative antiplatelet agents (e.g. prasugrel or ticagrelor with lower dosing) or additional gastric protection rather than shortening the full 12-month course.

What does a DAPT score of 0 or 1 mean in practical terms?

A score of 0 or 1 indicates that your predicted benefit from extended DAPT is outweighed by bleeding complications. After completing 12 months of dual therapy without adverse events, you can transition to aspirin alone with confidence that single-agent therapy provides equivalent long-term outcomes. Your cardiologist may still recommend aspirin indefinitely, as it prevents additional cardiac events beyond stent-related complications.

How accurate is the DAPT calculator?

The DAPT score was derived from over 11,000 patients in randomised trials and external validation studies, demonstrating good discrimination between high and low-risk groups. However, it is a population-level tool; individual patients may experience outcomes that differ from group predictions. Additional clinical factors—frailty, liver dysfunction, or genetic variation in drug metabolism—influence the actual risk. The calculator should be used alongside your doctor's assessment, not in isolation.

If I have diabetes and prior MI, should I automatically stay on DAPT longer?

Diabetes and prior MI each contribute one point to the DAPT score, raising it toward the prolonged DAPT threshold. However, two points alone do not mandate extended therapy. Your final score depends on all nine variables and your age adjustment. A 70-year-old with diabetes and prior MI might still score 0 or 1 after the −1 age deduction, warranting monotherapy. Conversely, a younger patient with these factors plus additional risk factors could score ≥2. Your cardiologist will weigh the complete picture.

What should I do if I experience bleeding while on dual antiplatelet therapy?

Report any unusual bleeding—including nosebleeds, heavy menstrual bleeding, black or bloody stools, or bruising—to your cardiologist immediately. Minor bleeding alone does not mandate stopping both drugs, but it may prompt a switch to lower-dose regimens, addition of gastric protection (proton pump inhibitor), or earlier transition to monotherapy. Major bleeding (hospitalisation-level) is a medical emergency requiring immediate evaluation and possible temporary cessation of antiplatelet agents.

Can the DAPT score be recalculated if my health changes?

The DAPT score is a snapshot based on your clinical status at the time of stent placement. Subsequent events—such as recurrent MI, development of heart failure, or bleeding complications—alter your risk profile. Your cardiologist may re-evaluate the risk-benefit ratio in light of new information, but the original DAPT score itself does not change. The tool is most relevant during the decision-making phase at and around 12 months post-PCI.

More health calculators (see all)

Waist-to-Height Ratio Calculator Ankle-Brachial Index Calculator Vital Capacity Calculator ECG Boxes to Seconds Calculator Breast Pump Flange Size Calculator Maintenance Fluids for Children Calculator FEV1/FVC Ratio Calculator Sodium Change in Hypertriglyceridemia Calculator